Metronidazole Vaginal Gel, 0.75%

Dosage for metronidazole is highly individualized based on the type of infection and the patient's overall health. According to the FDA-approved labeling, typical adult regimens include:

• Amebiasis (Intestinal or Liver Abscess): 500 mg to 750 mg taken orally three times daily for 5 to 10 days.
• Trichomoniasis: A common regimen is a single 2-gram dose (four 500 mg tablets) taken at once. Alternatively, a 7-day course of 250 mg three times daily or 500 mg twice daily may be prescribed to reduce the risk of recurrence. It is critical that sexual partners are treated simultaneously to prevent reinfection.
• Anaerobic Bacterial Infections: For serious systemic infections, the usual adult oral dose is 7.5 mg/kg every 6 hours (approximately 500 mg for a 70 kg adult). The total daily dose should generally not exceed 4 grams.
• Bacterial Vaginosis: 500 mg orally twice daily for 7 days is a standard regimen for non-pregnant patients.

Metronidazole is used in pediatric populations, though dosing is strictly weight-based.

• Amebiasis: The standard pediatric dose is 35 to 50 mg/kg/24 hours, divided into three doses, for 10 days.
• Other Infections: For anaerobic infections, pediatric dosing is typically 15 to 30 mg/kg/day.

Healthcare providers must carefully calculate these doses to ensure safety and efficacy in children. Always consult a pediatrician for specific instructions.

Renal Impairment

In patients with end-stage renal disease (ESRD), metronidazole and its metabolites can accumulate. While standard doses may be used for short courses, clinicians may monitor for toxicity. For patients on hemodialysis, metronidazole is rapidly removed; therefore, a supplemental dose may be administered immediately following the dialysis session.

Hepatic Impairment

Because metronidazole is primarily metabolized in the liver, patients with severe hepatic impairment (liver disease) process the drug slowly. This can lead to plasma accumulation and increased risk of adverse effects. In these cases, healthcare providers typically reduce the dose by 50% or increase the interval between doses.

Elderly Patients

Geriatric patients may have decreased hepatic or renal function. Clinicians often start at the lower end of the dosing range and monitor closely for neurological side effects, such as dizziness or confusion.

To ensure the medication works effectively and to minimize side effects, follow these guidelines:

• With or Without Food: Metronidazole tablets can be taken with food or a full glass of water or milk to reduce stomach upset.
• Extended-Release (ER) Tablets: ER versions should be taken on an empty stomach (at least 1 hour before or 2 hours after a meal). These tablets must be swallowed whole; do not crush, chew, or break them, as this destroys the controlled-release mechanism.
• Consistency: Take the medication at the same time each day to maintain a steady level in your bloodstream.
• Complete the Course: Even if symptoms improve within a few days, you must finish the entire prescribed course. Stopping early can allow the infection to return and may contribute to antimicrobial resistance.
• Storage: Store at room temperature (68°F to 77°F), away from moisture, heat, and direct light.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up, as this increases the risk of toxicity.

Signs of metronidazole overdose may include nausea, vomiting, ataxia (loss of muscle coordination), and slight disorientation. In severe cases, seizures or peripheral neuropathy may occur. If an overdose is suspected, contact a Poison Control Center or seek emergency medical attention immediately. Treatment is primarily supportive, as there is no specific antidote for metronidazole poisoning.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without medical guidance.

Many patients taking metronidazole experience mild to moderate side effects. The most frequently reported include:

• Metallic Taste (Dysgeusia): A sharp, unpleasant metallic taste in the mouth is very common. This usually resolves once the medication is discontinued.
• Nausea and Stomach Upset: Patients may feel 'queasy' or experience a loss of appetite. Taking the medication with food can often mitigate this.
• Darkened Urine: Urine may turn a reddish-brown or darker color. This is a harmless side effect caused by the drug's metabolites and is not a cause for alarm.
• Headache: Mild to moderate headaches may occur during the first few days of treatment.

• Diarrhea or Constipation: Changes in bowel habits are possible as the drug affects the gut microbiome.
• Dizziness or Lightheadedness: Some patients report feeling unsteady, particularly when rising quickly.
• Dry Mouth or Furry Tongue: A sensation of dryness in the mouth or a visible coating on the tongue (glossitis) may occur.
• Abdominal Cramping: Sharp or dull pains in the stomach area.

• Leukopenia: A temporary decrease in white blood cell counts, which may slightly increase the risk of infection.
• Pancreatitis: Inflammation of the pancreas, characterized by severe upper abdominal pain radiating to the back.
• Psychotic Reactions: Rare instances of confusion, hallucinations, or depression have been reported.

> Warning: Stop taking Metronidazole and call your doctor immediately if you experience any of these serious symptoms:

• Peripheral Neuropathy: This is characterized by tingling, numbness, or a 'pins and needles' sensation in the hands or feet. If ignored, this can become permanent.
• Central Nervous System (CNS) Toxicity: Symptoms include seizures (convulsions), encephalopathy (brain dysfunction), ataxia (clumsiness), or tremors. These are medical emergencies.
• Severe Allergic Reactions (Anaphylaxis): Signs include hives, itching, swelling of the face or throat, and difficulty breathing.
• Stevens-Johnson Syndrome (SJS): A rare but life-threatening skin reaction. Watch for flu-like symptoms followed by a painful red or purplish rash that spreads and blisters.
• Aseptic Meningitis: Symptoms include fever, headache, stiff neck, and sensitivity to light, occurring without a bacterial cause.
• Liver Injury: Yellowing of the eyes or skin (jaundice), dark urine, or severe right-sided abdominal pain, especially in patients with Cockayne syndrome.

Metronidazole is generally intended for short-term use (usually 7 to 14 days). Prolonged or repeated use can lead to:

• Superinfection: Overgrowth of non-susceptible organisms, such as Candida (yeast infection) or Clostridium difficile-associated diarrhea (CDAD).
• Persistent Neuropathy: If the drug is continued after the onset of tingling or numbness, the nerve damage may not be fully reversible.
• Carcinogenicity Concerns: In high-dose animal studies, metronidazole has been shown to be carcinogenic. While this has not been definitively proven in humans, the FDA recommends avoiding unnecessary use of the drug.

Historically, metronidazole carried a black box warning regarding its carcinogenic potential in mice and rats. While the 'Boxed Warning' format has changed in newer labeling, the core warning remains: Metronidazole has been shown to be carcinogenic in mice and rats. Unnecessary use of the drug should be avoided. Its use should be reserved for the conditions described in the indications section. This highlights the importance of using this antibiotic only when a bacterial or parasitic infection is confirmed or strongly suspected.

Report any unusual symptoms to your healthcare provider immediately to ensure your safety throughout the treatment course.

Metronidazole is a powerful antimicrobial that requires careful monitoring. Patients must be aware of the risk of neurological toxicity and the potential for severe reactions when combined with certain substances. It is vital to disclose your full medical history, especially any history of blood disorders, liver disease, or neurological conditions, to your healthcare provider before starting treatment.

Metronidazole is associated with a risk of carcinogenicity. According to the FDA, metronidazole has been shown to be carcinogenic in mice and rats in experimental studies. Because of this, it should only be used for its approved indications. Patients should not use this medication for viral infections (like the common cold) or for any condition not specifically prescribed by a doctor. Healthcare providers aim to use the shortest effective course to minimize potential risks.

• Neurological Effects: Metronidazole can cause serious CNS issues, including convulsive seizures and peripheral neuropathy. If you experience numbness, tingling, or any unusual muscle movements, contact your doctor immediately. The drug should be discontinued if these symptoms appear.
• Hepatotoxicity in Cockayne Syndrome: Patients with Cockayne syndrome (a rare multisystem disorder) are at risk for severe, irreversible, and potentially fatal liver failure when taking metronidazole. Liver function tests must be monitored if use is deemed absolutely necessary in this population.
• Blood Dyscrasias: Metronidazole is a nitroimidazole and should be used with caution in patients with evidence or history of blood dyscrasia (blood disorders). A mild leukopenia (low white blood cell count) has been observed during its administration.
• Allergic Reactions: Anaphylaxis and severe skin reactions like Stevens-Johnson Syndrome have been reported. Seek emergency care for any signs of a severe rash or breathing difficulty.

For most short-term users, routine lab tests are not required. However, for those on prolonged therapy or with underlying health issues, healthcare providers may order:

• Complete Blood Count (CBC): To monitor for leukopenia or other blood cell changes.
• Liver Function Tests (LFTs): To ensure the liver is processing the drug safely, especially in high-risk patients.
• Neurological Exams: To check for early signs of nerve damage or CNS toxicity.

Metronidazole may cause dizziness, confusion, hallucinations, or even seizures in some patients. You should not drive, operate heavy machinery, or engage in hazardous activities until you know how this medication affects you. If you feel lightheaded or confused, avoid these tasks and consult your healthcare provider.

Strict Avoidance of Alcohol is Required. Consuming alcohol while taking metronidazole, and for at least three days after the last dose, can cause a 'disulfiram-like reaction.' This is a severe chemical reaction characterized by abdominal cramps, nausea, vomiting, headaches, and flushing (redness of the face). This also applies to products containing propylene glycol (found in some liquid medications).

There is no specific tapering requirement for metronidazole, as it does not cause a physical withdrawal syndrome. However, stopping the medication too early can lead to 'treatment failure' or the development of antibiotic-resistant bacteria. Always finish the full course as prescribed by your doctor.

> Important: Discuss all your medical conditions with your healthcare provider before starting Metronidazole to ensure it is the safest choice for you.

• Alcohol (Ethanol): As mentioned, the combination of alcohol and metronidazole results in a disulfiram-like reaction. This occurs because metronidazole inhibits the enzyme acetaldehyde dehydrogenase, leading to a toxic buildup of acetaldehyde in the blood. This can cause severe vomiting, tachycardia (rapid heartbeat), and extreme discomfort.
• Disulfiram (Antabuse): Patients who have taken disulfiram within the last two weeks should not take metronidazole. Combining these two can lead to acute psychosis and states of confusion.

• Warfarin and Other Oral Anticoagulants: Metronidazole can significantly potentiate the anticoagulant effect of warfarin. It inhibits the metabolism of warfarin (specifically the CYP2C9 pathway), leading to a prolonged prothrombin time and an increased risk of bleeding. Patients on warfarin may need their dose adjusted and their INR (International Normalized Ratio) monitored closely.
• Lithium: Metronidazole has been reported to increase serum lithium levels, which can lead to lithium toxicity. Signs of toxicity include tremors, thirst, and confusion. Renal function and lithium levels should be checked regularly if these drugs are used together.
• Busulfan: Metronidazole can increase the plasma concentrations of busulfan (a chemotherapy drug), leading to an increased risk of serious busulfan toxicity, such as liver damage or lung issues.

• Phenytoin and Phenobarbital: These anti-seizure medications can induce liver enzymes, which speeds up the metabolism of metronidazole. This can lower the levels of metronidazole in the blood, potentially making it less effective against the infection.
• Cimetidine: This heartburn medication can inhibit liver enzymes, potentially increasing the levels of metronidazole in the body and increasing the risk of side effects.
• 5-Fluorouracil (5-FU): Metronidazole may decrease the clearance of 5-FU, increasing its toxicity.

• Alcoholic Beverages and Foods: This is the primary concern. Avoid all alcohol, including wine, beer, and spirits. Also, check labels for alcohol in sauces, desserts, or mouthwashes.
• General Diet: There are no specific restrictions on dairy, grapefruit, or high-fat meals. However, taking the drug with food is generally recommended to prevent gastrointestinal upset.

• St. John's Wort: This herbal supplement is a potent inducer of certain enzymes and may potentially reduce the efficacy of metronidazole, though specific data is limited.
• Milk Thistle: Some studies suggest milk thistle might affect liver enzymes involved in drug metabolism, so caution is advised.

Metronidazole can interfere with certain chemical analyses of serum chemistry, such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), triglycerides, and glucose hexokinase. It may cause these values to appear falsely low (specifically when using methods that involve a decrease in ultraviolet absorbance at 340 nm). Always inform the laboratory staff that you are taking metronidazole if you are undergoing blood tests.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A comprehensive review of your current regimen is the best way to prevent dangerous drug interactions.

There are several scenarios where metronidazole must never be used due to the risk of life-threatening complications:

1. 1Hypersensitivity: Patients with a known allergy to metronidazole or other nitroimidazole derivatives (such as tinidazole) must not take this drug. An allergic reaction can range from a mild rash to fatal anaphylaxis.
2. 2First Trimester of Pregnancy in Trichomoniasis: While the data is nuanced, the FDA-approved labeling generally contraindicates the use of metronidazole for the treatment of trichomoniasis during the first trimester of pregnancy to avoid any potential risk to the developing fetus.
3. 3Alcohol or Disulfiram Use: As detailed in the interactions section, use of alcohol within 3 days (before or after) or disulfiram within 2 weeks is an absolute contraindication due to the risk of severe toxicity and psychosis.
4. 4Cockayne Syndrome: Due to the high risk of fatal hepatotoxicity (liver failure), metronidazole is contraindicated in these patients unless no alternative treatment exists.

In these conditions, a healthcare provider will perform a careful risk-benefit analysis:

• Active CNS Disease: Because metronidazole can cross the blood-brain barrier and cause neurotoxicity, patients with epilepsy or other neurological disorders must be monitored with extreme caution.
• Severe Liver Disease: Since the liver is the primary metabolic site, impaired function can lead to drug buildup. Dose reductions are typically required.
• Blood Dyscrasias: Patients with a history of low white blood cell counts may experience a worsening of their condition.

Patients who have had an adverse reaction to other nitroimidazoles, such as tinidazole or secnidazole, are highly likely to react to metronidazole. Cross-sensitivity is common within this chemical class, and these patients should generally avoid all drugs in the nitroimidazole category.

> Important: Your healthcare provider will evaluate your complete medical history, including any rare genetic conditions or previous drug allergies, before prescribing Metronidazole.

Metronidazole crosses the placental barrier. According to the FDA, it is classified in a way that suggests caution. While many studies and meta-analyses (including a large review by the CDC) have not shown a consistent link between metronidazole use and birth defects or miscarriage, its use during the first trimester for trichomoniasis is contraindicated. For other serious infections, healthcare providers weigh the risk of the untreated infection against the potential risk to the fetus. It should be used during pregnancy only if clearly needed and under strict medical supervision.

Metronidazole is excreted into human breast milk in concentrations similar to those found in the mother's blood. Because animal studies have shown a potential for carcinogenicity, many experts suggest a 'pump and discard' approach. If a mother must take a single large dose (e.g., 2 grams for trichomoniasis), it is often recommended to interrupt breastfeeding for 12 to 24 hours after the dose to allow the drug to clear from the milk. For longer courses, your doctor may recommend alternative feeding methods or a different antibiotic if possible.

Metronidazole is approved for use in children for specific conditions like amebiasis. However, its safety and effectiveness for other uses in pediatric patients have not been as extensively established. Pediatricians must carefully calculate doses based on weight (mg/kg). Long-term effects on growth and development have not been fully characterized, so use is typically limited to the shortest duration necessary.

Older adults are more susceptible to the side effects of metronidazole, particularly the neurological effects like confusion or dizziness. Because kidney and liver function naturally decline with age, the drug may stay in the body longer. Clinical studies have shown that the half-life of the drug can be prolonged in the elderly. Healthcare providers often start with lower doses and monitor liver function more frequently in this population.

In patients with a reduced Glomerular Filtration Rate (GFR), the parent drug is still cleared relatively well, but its metabolites can accumulate. For patients with severe renal failure (GFR < 10 mL/min), monitoring for toxicity is essential. For those on hemodialysis, the drug is removed quickly (half-life drops to about 3 hours), so doses are typically timed to be given after the dialysis session.

Patients with significant liver disease (e.g., Child-Pugh Class C) have a significantly reduced clearance of metronidazole. This can lead to toxic plasma levels. In these patients, the total daily dose is often reduced by 50% or more. Frequent monitoring of plasma levels, if available, or close clinical observation for neurological side effects is mandatory.

> Important: Special populations require individualized medical assessment to ensure that the benefits of metronidazole therapy outweigh the potential risks.

Metronidazole is a member of the nitroimidazole class. Its action is dependent on the reduction of its nitro group by anaerobic organisms. In these pathogens, the drug acts as an electron sink, intercepting electrons from ferredoxin-linked metabolic pathways. This reduction creates a highly reactive nitro radical anion. This radical causes extensive damage to the microbial DNA by inducing strand breaks and inhibiting the DNA repair enzyme systems. This 'suicide' mechanism ensures that the drug is only toxic to organisms capable of reducing it, which primarily includes anaerobes and certain protozoa.

Metronidazole exhibits concentration-dependent killing, meaning that higher peak concentrations relative to the Minimum Inhibitory Concentration (MIC) of the pathogen lead to more effective eradication. It also possesses a significant post-antibiotic effect (PAE) against many anaerobes, meaning it continues to suppress bacterial growth even after the drug levels drop below the MIC. Resistance is relatively rare but can occur through the down-regulation of ferredoxin or the expression of 'nim' genes that detoxify the drug.

| Parameter | Value |

|---|---|

| Bioavailability | ~100% (Oral) |

| Protein Binding | <20% |

| Half-life | 8 hours (Adults) |

| Tmax | 1-2 hours |

| Metabolism | Hepatic (Oxidation/Glucuronidation) |

| Excretion | Renal (60-80%), Fecal (6-15%) |

The molecular formula for metronidazole is $C_6H_9N_3O_3$. It has a molecular weight of 171.15 g/mol. Chemically, it is 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethanol. It appears as a white to pale yellow crystalline powder and is sparingly soluble in water and alcohol. Its structure features a nitro group at the 5-position of the imidazole ring, which is the key to its antimicrobial activity.

Metronidazole is the prototype of the Nitroimidazole Antimicrobial class. Related medications include Tinidazole and Secnidazole. While these drugs share a similar mechanism, they differ in their half-lives and specific FDA-approved indications.